Advertisement
MEDP vs TMO
Which Stock Would AI Choose? Medpace Holdings (MEDP) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Medpace Holdings (MEDP) operates as a specialized clinical research organization (CRO) focused on drug and device development services, while Thermo Fisher Scientific (TMO) provides a broader portfolio of life sciences tools, diagnostics, and laboratory products.
- In recent market activity, MEDP has demonstrated stronger relative revenue growth tied to clinical trial demand compared with TMO’s exposure to broader research and biopharma spending patterns.
- TMO maintains significantly larger scale with market capitalization exceeding $200 billion and diversified revenue streams across four major segments, offering greater stability but potentially slower growth momentum.
- MEDP exhibits higher profitability margins and lower debt levels relative to its size, positioning it as a more agile player within the healthcare services sector.
- Both stocks operate in the healthcare diagnostics and research space, with recent performance influenced by biopharmaceutical R&D budgets and regulatory environments rather than single events.
- Market sentiment reflects MEDP’s outperformance in select periods versus TMO’s established leadership in analytical instruments and specialty diagnostics.
Introduction
Investors and traders seeking exposure to the healthcare research and diagnostics sector often evaluate specialized service providers alongside diversified instrument manufacturers. This comparison of MEDP and TMO examines their business models, recent performance trends, and relative positioning in the current market environment. The analysis is relevant for those assessing growth-oriented clinical development services against established life sciences platforms, particularly within portfolios focused on healthcare innovation and R&D spending cycles.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) delivers outsourced clinical development services to pharmaceutical, biotechnology, and medical device companies. Its full-service model supports trials from Phase I through IV across multiple therapeutic areas, including bioanalytical and imaging support. In recent market activity, the stock has reflected steady demand for efficient clinical research amid ongoing biopharma pipelines. Performance has been shaped by revenue expansion from increased trial volumes and operational efficiencies, with sentiment supported by the company’s focused therapeutic expertise and global reach. Broader sector dynamics, including regulatory timelines and sponsor budgets, have influenced price behavior over recent weeks.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) supplies life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. The company operates through four segments serving research, clinical, and industrial customers worldwide. Recent market activity has shown measured responses to fluctuations in research funding and instrument demand, with performance tied to broader life sciences spending. Sentiment has been influenced by its scale advantages and recurring revenue from consumables, alongside exposure to evolving diagnostic and bioprocessing needs. Price movements over recent weeks have aligned with industry-wide patterns in healthcare capital expenditure.
Trending AI Robots
Tickeron’s Trending AI Robots page curates high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating superior adaptability to prevailing market conditions earn placement in this section. Bots feature varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical win rates and returns spanning wide ranges depending on market regimes. This resource allows users to explore data-driven approaches suited to specific equities like MEDP or TMO. Review the Trending AI Robots page for current selections and detailed statistics.
Head-to-Head Comparison
Medpace Holdings (MEDP) follows a service-oriented business model centered on clinical trial execution, offering higher growth potential from specialized demand but with greater sensitivity to trial starts and sponsor activity. Thermo Fisher Scientific (TMO) emphasizes product-based revenue across instruments and consumables, providing more diversified exposure and recurring income streams. Recent momentum has favored MEDP in growth metrics, while TMO benefits from larger scale and lower relative volatility. Risk factors include MEDP’s concentration in services versus TMO’s broader but capital-intensive operations. Sector exposure overlaps in healthcare R&D, yet MEDP aligns more closely with clinical development cycles and TMO with research infrastructure spending. Market sentiment reflects these trade-offs in relative valuation and performance consistency.
Tickeron AI Verdict
Based on observable factors such as trend consistency in clinical services demand, margin stability, and relative positioning within healthcare R&D, Tickeron’s AI would currently assign a higher probabilistic preference to MEDP over TMO. This assessment considers MEDP’s demonstrated growth alignment with specialized trial activity versus TMO’s more measured response to broader market variables. Outcomes remain subject to evolving sector conditions and individual portfolio objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDP is a StrongBuy and TMO is a Buy.
MEDP | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 24 | 77 | |
SMR RATING 1..100 | 11 | 60 | |
PRICE GROWTH RATING 1..100 | 44 | 28 | |
P/E GROWTH RATING 1..100 | 40 | 15 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for MEDP (72) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew somewhat faster than MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (24) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (77) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
MEDP's SMR Rating (11) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (60) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (28) in the Medical Specialties industry is in the same range as MEDP (44) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
TMO's P/E Growth Rating (15) in the Medical Specialties industry is in the same range as MEDP (40) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
| MEDP | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 50% |
| Stochastic ODDS (%) | 4 days ago 83% | 4 days ago 52% |
| Momentum ODDS (%) | 4 days ago 55% | 4 days ago 61% |
| MACD ODDS (%) | 4 days ago 62% | 4 days ago 53% |
| TrendWeek ODDS (%) | 4 days ago 60% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 77% | 4 days ago 62% |
| Advances ODDS (%) | 6 days ago 76% | 7 days ago 63% |
| Declines ODDS (%) | 8 days ago 63% | 5 days ago 62% |
| BollingerBands ODDS (%) | 4 days ago 81% | 4 days ago 55% |
| Aroon ODDS (%) | 4 days ago 83% | 4 days ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEDP’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- MEDP’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MEDP’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- MEDP’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
MEDP (@Medical Specialties) experienced а -3.14% price change this week, while TMO (@Medical Specialties) price change was -2.99% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.42%. For the same industry, the average monthly price growth was +6.10%, and the average quarterly price growth was +49.42%.
Reported Earning Dates
MEDP is expected to report earnings on Oct 21, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical Specialties (+0.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with TMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | +0.23% | ||
| TMO - MEDP | 61% Loosely correlated | +0.35% | ||
| CRL - MEDP | 57% Loosely correlated | +1.17% | ||
| A - MEDP | 44% Loosely correlated | +0.66% | ||
| RVTY - MEDP | 44% Loosely correlated | +1.66% | ||
| BRKR - MEDP | 43% Loosely correlated | +2.10% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +0.35% | ||
| A - TMO | 74% Closely correlated | +0.66% | ||
| DHR - TMO | 73% Closely correlated | +1.09% | ||
| RVTY - TMO | 70% Closely correlated | +1.66% | ||
| IQV - TMO | 69% Closely correlated | -0.96% | ||
| BRKR - TMO | 67% Closely correlated | +2.10% | ||
More | ||||